AIM ImmunoTech (AIM) announced that the first new subject has been dosed in Phase 2 of the Phase 1b/2 clinical trial involving AIM’s Ampligen and AstraZeneca’s (AZN) anti-PD-L1 immune checkpoint inhibitor Imfinzi in the treatment of late-stage pancreatic cancer. Several subjects from Phase 1 who received the highest dose will also be included in Phase 2. DURIPANC is an investigator-initiated, exploratory, open-label, single-center study in the Netherlands at the Erasmus Medical Center. Up to 25 patients are expected to be enrolled in the Phase 2 portion of DURIPANC.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AIM:
- AIM ImmunoTech to not proceed with offering pursuant to registration statement
- AIM ImmunoTech announces follow-up clinical study of Ampligen with FluMist
- AIM ImmunoTech announces Safety Committee approval to proceed with Phase 2
- AIM ImmunoTech files to sell units, no amount given
- AIM ImmunoTech announces publication of clinical study results for AMP-518 trial